Insurance holding company Globe Life (NYSE: GL) met Wall Street’s revenue expectations in Q3 2026, with sales up 6% year on year to $1.61 billion. Its non-GAAP profit of $4.84 per share was 1.1% below analysts’ consensus estimates.

Is now the time to buy GL? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Globe Life’s third quarter saw solid revenue growth, yet the market responded negatively after adjusted earnings came in below analyst expectations. Management pointed to operational headwinds in its United American General Agency Division, most notably due to a process change at the Centers for Medicare & Medicaid Services (CMS) that led to elevated claims. Additionally, the Evri group health business experienced higher-than-expected severity in claims, contributing to lower underwriting margins. Co-CEO Frank Martin Svoboda acknowledged, “Underwriting results this quarter were adversely impacted by a process change at CMS…and high severity claims at Evri.”

Looking ahead, Globe Life’s guidance is shaped by expectations of continued premium growth in both life and health lines but tempered by lingering volatility in health margins and the evolving mix of its business. Management emphasized ongoing rate increases, expansion in agent recruiting and productivity, and the scaling of new business channels as key levers. Co-CEO James Matthew Darden added that changes to agent compensation are expected to support sales growth, while CFO Thomas Peter Kalmbach noted that pricing adjustments and increased scale at Evri should reduce margin volatility over time. The company also highlighted increased flexibility from reciprocal jurisdiction approval, enabling broader capital management strategies.

Key insights from management’s remarks

Management attributed the quarter’s mixed performance to operational challenges in Medicare supplement claims processing and the impact of high-severity group health claims, while also highlighting ongoing investments in agent productivity and digital marketing adaptation.

• Medicare claims process disruption: The United American General Agency faced elevated claims due to a CMS process change, resulting in out-of-period payments and a temporary spike in health loss ratios. Management believes this disruption is largely resolved and will normalize in future periods.

• Group health volatility at Evri: The Evri business, which markets group health products through brokers, experienced an underwriting loss from a handful of high-severity claims. Management noted the need for greater scale to stabilize results and is implementing pricing and renewal strategies to improve profitability.

• Agent productivity and compensation: Adjustments to agent compensation structures at American Income Life have improved productivity and stabilized agent count after a period of decline. Management expects further compensation changes later in the year to support recruiting and retention, aiming for mid- to high-single-digit sales growth in 2027.

• Digital marketing transition: The Direct to Consumer channel is adapting to shifts in digital advertising, including AI-powered search changes affecting inquiry rates. New initiatives, such as AI-enabled advertising, have shown early signs of improving lead generation.

• Investment and capital flexibility: Reciprocal jurisdiction approval from regulators allows Globe Life to optimize capital allocation, including increased reinsurance activity with its Bermuda subsidiary. Management expects this to enhance financial flexibility and support share repurchases and dividends in the coming years.

Drivers of future performance

Globe Life’s outlook for the next year centers on expected growth in premiums, improved agent productivity, and margin stabilization efforts—balanced against persistent volatility in the group health portfolio and evolving regulatory and competitive dynamics.

• Group health risk management: Management is focused on scaling the Evri group health business to reduce the impact of high-severity claims. Pricing actions and underwriting discipline are being applied, but volatility may persist until the business reaches greater scale and risk is better diversified.

• Agent-driven growth initiatives: Expanding agent count and productivity, particularly at Liberty National and American Income Life, is expected to drive sales growth. New compensation structures are intended to enhance recruiting and retention, though the transition period adds some uncertainty.

• Capital strategy and reinsurance: Globe Life is leveraging reciprocal jurisdiction approval to increase reinsurance activities with its Bermuda subsidiary, freeing up capital at the parent level. This is expected to support ongoing share repurchases and dividend payments, though regulatory approval processes and subsidiary capital needs remain key variables.

Catalysts in upcoming quarters

Looking ahead, the StockStory team will be monitoring (1) the stabilization of group health margins at Evri as pricing changes and scale develop, (2) progress in agent recruiting and productivity across major channels, and (3) continued adaptation to digital marketing trends in the Direct to Consumer business. Additionally, we will track the pace and regulatory approval of reinsurance transactions with the Bermuda subsidiary and their impact on capital flexibility.

Globe Life currently trades at $163.17, down from $169.62 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.